{
    "name": "caspofungin",
    "comment": "Rx",
    "other_names": [
        "Cancidas"
    ],
    "classes": [
        "Antifungals",
        "Systemic",
        "Antifungals",
        "Echinocandin"
    ],
    "source": "https://reference.medscape.com/drug/cancidas-caspofungin-342584",
    "pregnancy": {
        "common": [
            "There are insufficient human data to establish whether there is a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes in pregnant women"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal studies, drug caused embryofetal toxicity, including increased resorptions, increased peri-implantation loss, and incomplete ossification at multiple fetal sites when administered intravenously to pregnant rats and rabbits during organogenesis at doses up to 0.8 and 2 times the clinical dose, respectively; advise patients of potential risk to fetus; estimated background risk of major birth defects and miscarriage for indicated population is unknown; all pregnancies have a background risk of birth defect, loss, or other adverse outcomes"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human milk, effects on breast-fed child, or on milk production",
            "Drug was found in milk of lactating, drug-treated rats; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for drug and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to drug or components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Do not use dextrose diluents",
                "Do not use with cyclosporine (unless benefits outweigh risks)",
                "Not for bolus administration",
                "Cyclosporine may increase AUC of caspofungin by approximately 35%",
                "Anaphylaxis reported, discontinue and administer appropriate treatment; possible histamine-mediated adverse reactions, including rash, facial swelling, angioedema, pruritus, sensation of warmth or bronchospasm",
                "Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), some with a fatal outcome, reported; discontinue use at first sign or symptom of a hypersensitivity reaction and administer appropriate treatment",
                "Some adult and pediatric patients with serious underlying conditions receiving multiple concomitant medications with this drug, isolated cases of clinically significant hepatic dysfunction, hepatitis, and hepatic failure reported; a causal relationship has not been established; monitor patients who develop abnormal liver function tests during therapy for evidence of worsening hepatic function and evaluated for risk/benefit of continuing therapy"
            ],
            "specific": [
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Elevated liver enzymes reported in patients receiving this medication and cyclosporine concomitantly; only use concomitantly with cyclosporine in patients for whom potential benefit outweighs potential risk; patients who develop abnormal liver enzymes during concomitant therapy, should be monitored, and risk/benefit of continuing therapy evaluated"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine will increase the level or effect of caspofungin by  Other (see comment). Avoid or Use Alternate Drug. may increase plasma concentrations of OATP substrates"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "caspofungin increases levels of eluxadoline by decreasing metabolism. Avoid or Use Alternate Drug. Decrease eluxadoline dose to 75 mg PO BID if coadministered with OATP1B1 inhibitors. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of caspofungin by  Other (see comment). Avoid or Use Alternate Drug. Leniolisib, an OATP1B1 and OATP1B3 inhibitor, may increase systemic exposure of these substrates "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Saccharomyces boulardii",
            "description": {
                "common": "caspofungin decreases effects of Saccharomyces boulardii by unspecified interaction mechanism. Avoid or Use Alternate Drug. Systemic or oral antifungals may decrease activity of probiotic."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trofinetide",
            "description": {
                "common": "trofinetide will increase the level or effect of caspofungin by  Other (see comment). Avoid or Use Alternate Drug. Trofinetide (an OATP131 and OATP13B inhibitor) may increase plasma levels of OATP131 or OATP13B substrates. Avoid coadministration with sensitive substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of caspofungin by  increasing elimination. Use Caution/Monitor. Apalutamide weakly induces OATP1B1 and may decrease systemic exposure of drugs that are OATP1B1 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "caspofungin increases toxicity of atorvastatin by Other (see comment). Use Caution/Monitor. \nComment: OATP1B1 inhibitors may increase risk of myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine decreases levels of caspofungin by increasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "caspofungin and deflazacort both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and caspofungin both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will increase the level or effect of caspofungin by  Other (see comment). Modify Therapy/Monitor Closely. Encorafenib (a OATP1B1 inhibitor) may increase the concentration and toxicities of OATP1B1 substrates. Closely monitor for signs and symptoms of increased exposure and consider adjusting the dose of these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "caspofungin increases toxicity of fluvastatin by Other (see comment). Use Caution/Monitor. \nComment: OATP1B1 inhibitors may increase risk of myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "fostemsavir will increase the level or effect of caspofungin by  Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits OATP1B1/3 transporter. If possible, avoid coadministration or modify dose of OATP1B1/3 substrates coadministered with fostemsavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "caspofungin will increase the level or effect of glecaprevir/pibrentasvir by  decreasing metabolism. Use Caution/Monitor. Caution when coadministering glecaprevir/pibrentasvir with OATP1B1/OATP1B3 inhibitors"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "caspofungin increases levels of letermovir by decreasing metabolism. Use Caution/Monitor. Coadminstration of letermovir, an OATP1B1/3 substrate, with OATP1B1/3 inhibitors may increase letermovir plasma concentrations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pitavastatin",
            "description": {
                "common": "caspofungin increases toxicity of pitavastatin by Other (see comment). Use Caution/Monitor. \nComment: OATP1B1 inhibitors may increase risk of myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pravastatin",
            "description": {
                "common": "caspofungin increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. \nComment: OATP1B1 inhibitors may increase risk of myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin decreases levels of caspofungin by increasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosuvastatin",
            "description": {
                "common": "caspofungin increases toxicity of rosuvastatin by Other (see comment). Use Caution/Monitor. \nComment: OATP1B1 inhibitors may increase risk of myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "caspofungin will increase the level or effect of sacubitril/valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "simvastatin",
            "description": {
                "common": "caspofungin will increase the level or effect of simvastatin by  Other (see comment). Use Caution/Monitor. OATP1B1 inhibitors may increase risk of myopathy"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol",
            "description": {
                "common": "caspofungin and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sofosbuvir/velpatasvir",
            "description": {
                "common": "sofosbuvir/velpatasvir increases levels of caspofungin by Other (see comment). Use Caution/Monitor. \nComment: Velpatasvir inhibits OATP1B1, OATP1B3, and OATP2B1 transporters. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "caspofungin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, caspofungin.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases levels of caspofungin by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz decreases levels of caspofungin by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethotoin",
            "description": {
                "common": "ethotoin decreases levels of caspofungin by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin decreases levels of caspofungin by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir decreases levels of caspofungin by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine decreases levels of caspofungin by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin decreases levels of caspofungin by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "caspofungin decreases levels of tacrolimus by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin will increase the level or effect of caspofungin by  Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Varies with condition",
            "percent": "20-35"
        },
        {
            "name": "Anaphylaxis reported during administration of Cancidas",
            "percent": "6-30"
        },
        {
            "name": "Infused vein complications",
            "percent": "6-27"
        },
        {
            "name": "phlebitis",
            "percent": "9-23"
        },
        {
            "name": "Fever",
            "percent": "4-23"
        },
        {
            "name": "Diarrhea",
            "percent": "9-22"
        },
        {
            "name": "Shivering",
            "percent": "3-20"
        },
        {
            "name": "Rash",
            "percent": "2-20"
        },
        {
            "name": "Increased serum alkaline phosphatase",
            "percent": "2-18"
        },
        {
            "name": "Hypotension",
            "percent": "11"
        },
        {
            "name": "Respiratory failure",
            "percent": "14"
        },
        {
            "name": "Incr transaminases",
            "percent": "9"
        },
        {
            "name": "Septic shock",
            "percent": "8"
        },
        {
            "name": "to",
            "percent": null
        },
        {
            "name": "Pleural effusion",
            "percent": null
        },
        {
            "name": "Respiratory distress",
            "percent": null
        },
        {
            "name": "up to",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Decreased Hgb",
            "percent": null
        },
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "Chills",
            "percent": null
        },
        {
            "name": "Hypokalemia",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Facial edema",
            "percent": null
        },
        {
            "name": "flushing",
            "percent": null
        },
        {
            "name": "Hematuria",
            "percent": null
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": null
        },
        {
            "name": "Increased serum creatinine",
            "percent": null
        },
        {
            "name": "Induration",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Pain",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Sepsis",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Hepatic necrosis",
            "percent": null
        },
        {
            "name": "Liver failure",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "Nephrotoxicity",
            "percent": null
        },
        {
            "name": "Renal impairment",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "coagulopathy",
            "percent": null
        },
        {
            "name": "febrile neutropenia",
            "percent": null
        },
        {
            "name": "neutropenia",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Arrhythmia",
            "percent": null
        },
        {
            "name": "atrial fibrillation",
            "percent": null
        },
        {
            "name": "bradycardia",
            "percent": null
        },
        {
            "name": "cardiac arrest",
            "percent": null
        },
        {
            "name": "myocardial infarction",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Abdominal distension",
            "percent": null
        },
        {
            "name": "abdominal pain upper",
            "percent": null
        },
        {
            "name": "constipation",
            "percent": null
        },
        {
            "name": "dyspepsia",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "fatigue",
            "percent": null
        },
        {
            "name": "infusion site pain",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        },
        {
            "name": "mucosal inflammation",
            "percent": null
        },
        {
            "name": "peripheral edema",
            "percent": null
        },
        {
            "name": "Hepatobiliary disorders",
            "percent": null
        },
        {
            "name": "Hepatic failure",
            "percent": null
        },
        {
            "name": "hepatomegaly",
            "percent": null
        },
        {
            "name": "hepatotoxicity",
            "percent": null
        },
        {
            "name": "hyperbilirubinemia",
            "percent": null
        },
        {
            "name": "jaundice",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Bacteremia",
            "percent": null
        },
        {
            "name": "sepsis",
            "percent": null
        },
        {
            "name": "urinary tract infection Metabolic and nutrition disorders",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "decreased appetite",
            "percent": null
        },
        {
            "name": "fluid overload",
            "percent": null
        },
        {
            "name": "hypomagnesemia",
            "percent": null
        },
        {
            "name": "hypercalcemia",
            "percent": null
        },
        {
            "name": "hyperglycemia",
            "percent": null
        },
        {
            "name": "hypokalemia",
            "percent": null
        },
        {
            "name": "Musculoskeletal",
            "percent": null
        },
        {
            "name": "connective tissue",
            "percent": null
        },
        {
            "name": "and bone disorders",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "back pain",
            "percent": null
        },
        {
            "name": "pain in extremity",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Convulsion",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "somnolence",
            "percent": null
        },
        {
            "name": "tremor",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "confusional state",
            "percent": null
        },
        {
            "name": "depression",
            "percent": null
        },
        {
            "name": "insomnia",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Hematuria",
            "percent": null
        },
        {
            "name": "renal failure",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "epistaxis",
            "percent": null
        },
        {
            "name": "hypoxia",
            "percent": null
        },
        {
            "name": "tachypnea",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "petechiae",
            "percent": null
        },
        {
            "name": "skin lesion",
            "percent": null
        },
        {
            "name": "skin exfoliation",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Flushing",
            "percent": null
        },
        {
            "name": "hypertension",
            "percent": null
        },
        {
            "name": "phlebitis",
            "percent": null
        }
    ]
}